MIRMHealthcare · BiotechnologyThe 14 Wall Street analysts covering Mirum Pharmaceuticals, Inc. hold a median 12-month price target of $137 — +41.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Mirum Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (91): The shares have been drifting up relative to others.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MIRM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +41.6% from it.
Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | Citizens | Maintains | Market Outperform | $146 → $137 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $185 → $140 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $148 → $135 |
| 6 Aug 2026 | TD Cowen | Maintains | Buy | $145 → $140 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $142 → $148 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 2 July 2026 | JP Morgan | Maintains | Overweight | — |
| 2 July 2026 | JP Morgan | Maintains | Overweight | $115 → $125 |
| 15 June 2026 | Citizens | Maintains | Market Outperform | — |
| 11 June 2026 | Morgan Stanley | Maintains | Overweight | — |
| 2 June 2026 | Citigroup | Initiates | Buy | — |
| 19 May 2026 | Wolfe Research | Initiates | Outperform | — |
| 7 May 2026 | Baird | Maintains | Outperform | — |
| 7 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 7 May 2026 | RBC Capital | Maintains | Outperform | — |
| 7 May 2026 | TD Cowen | Maintains | Buy | — |
| 5 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Apr 2026 | Stifel | Maintains | Buy | — |
| 28 Apr 2026 | Baird | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MIRM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Mirum Pharmaceuticals, Inc. returned +35.2% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 15% of US stocks
Cheaper than 99% of US stocks
Cheaper than 96% of US stocks
Higher than 82% of US stocks
Higher than 70% of US stocks
Higher than 92% of US stocks
Higher than 23% of US stocks
Higher than 4% of US stocks
Higher than 2% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Mirum Pharmaceuticals, Inc. has a market value of $5.9B and an enterprise value of $6.6B.
Revenue in the twelve months to 30 June 2026: $618.1M. The latest quarter grew 37.9% year on year.
Net income over the same four quarters: −$860.2M, a −139.2% net margin.
Diluted earnings per share, trailing twelve months: $−14.55.
Free cash flow in the twelve months to 30 June 2026: −$263.7M.
Trailing P/E: −204.7×; forward P/E: −277.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Mirum Pharmaceuticals, Inc. employs 433 people — $1.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Mirum Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Mirum Pharmaceuticals announced it has issued inducement grants under Nasdaq Listing Rule 5635(c)(4). The grants were made to new employees as an inducement to join the company.
Why it matters — MIRM watchers would note this as a standard corporate practice for attracting new talent, which could signal hiring momentum but does not directly impact near-term financials.
Mirum's second-quarter earnings missed estimates, while revenues beat expectations, driven by growth from Livmarli and its bile acid drugs. The company raised its 2026 sales outlook as a result of this revenue performance.
Why it matters — For MIRM watchers, the raised 2026 sales outlook and revenue beat signal continued growth momentum from its key Livmarli and bile acid products despite the earnings miss.
On Thursday, Insmed led a biotech rally, rising 30% on solid second-quarter sales for its lung disease drug Brinsupri. In the same session, Mirum Pharmaceuticals' shares fell sharply, as reflected in the headline "But Mirum Takes A Bath."
Why it matters — The article reports that Mirum's stock declined sharply during the same trading session, which is directly relevant to MIRM watchers tracking the company's share performance.
Mirum Pharmaceuticals published the transcript of its Q2 2026 earnings call on Seeking Alpha, providing a record of management's remarks during the call.
Why it matters — A MIRM watcher would care because the transcript offers a full account of the company's quarterly results and commentary beyond the headline figures.
Mirum Pharmaceuticals reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million. The company also outlined upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.
Why it matters — A MIRM watcher would care because the raised sales outlook and the described pipeline milestones indicate the company's commercial momentum and near-term catalyst schedule.
The 14 Wall Street analysts covering Mirum Pharmaceuticals, Inc. have a median 12-month price target of $137, with estimates ranging from $118 to $183. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Mirum Pharmaceuticals, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mirum Pharmaceuticals, Inc. 69 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Mirum Pharmaceuticals, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +41.6% from the last close, and Ticker Nerd's factor model ranks Mirum Pharmaceuticals, Inc. 69 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Mirum Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIRM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $118 to $183 over the next 12 months.
Mirum Pharmaceuticals, Inc. returned +35.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases.
The most recent item we track (Business Wire, 11 Aug 2026): "Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Mirum Pharmaceuticals announced it has issued inducement grants under Nasdaq Listing Rule 5635(c)(4). The grants were made to new employees as an inducement to join the company.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases. Its primary objective is to address unmet medical needs, particularly in the sphere of liver diseases where few treatment options exist. Mirum is especially recognized for its work on conditions like Alagille syndrome, a rare genetic disorder affecting the liver, heart, and other parts of the body. The company is committed to advancing its research to offer novel solutions, facilitating regulatory approval processes, and ensuring global access to its therapies. Mirum Pharmaceuticals plays an essential role in the healthcare sector, providing essential treatment options that can significantly improve the quality of life for patients with chronic and challenging illnesses. Its contributions are vital for advancements in the understanding and management of complex liver diseases, making it a key player in the biopharmaceutical landscape, serving the needs of niche patient populations with precision medicine.
CEO Mr. Christopher Peetz · 433 employees · United States · https://www.mirumpharma.com
